Statins do not influence long-term rituximab clinical efficiency in rheumatoid arthritis patients

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Mazilu, Diana ^a,b   Gudu, Tania ^a   Ionescu, Ruxandra ^a,b   Opris, Daniela ^a,b  

^a Sfanta Maria Hospital Bucharest   (Romania)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RITUXIMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DISEASE ACTIVITY SCORE; ERYTHROCYTE SEDIMENTATION RATE; EUROPEAN LEAGUE AGAINST RHEUMATISM; FEMALE; HUMAN; LONG TERM CARE; LONGITUDINAL STUDY; MALE; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; DRUG ANTAGONISM; DRUG INTERACTION; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; ROMANIA; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; ROMANIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893384529     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/689426     Document Type: Article

References (13)

1. Peters M. J. L., Symmons D. P. M., McCarey D., Dijkmans B. A. C., Nicola P., Kvien T. K., McInnes I. B., Haentzschel H., Gonzalez-Gay M. A., Provan S., Semb A., Sidiropoulos P., Kitas G., Smulders Y. M., Soubrier M., Szekanecz Z., Sattar N., Nurmohamed M. T., EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Annals of the Rheumatic Diseases 2010 69 2 325 331 2-s2.0-75749118959 10.1136/ard.2009.113696
2. Maradit-Kremers H., Nicola P. J., Crowson C. S., Ballman K. V., Gabriel S. E., Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis and Rheumatism 2005 52 3 722 732 2-s2.0-14944358734 10.1002/art.20878 (Pubitemid 40365093)
3. Gonzalez-Gay M. A., Gonzalez-Juanatey C., Lopez-Diaz M. J., Piñeiro A., Garcia-Porrua C., Miranda-Filloy J. A., Ollier W. E. R., Martin J., Llorca J., HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Care and Research 2007 57 1 125 132 2-s2.0-33846998295 10.1002/art.22482
4. Goodson N. J., Wiles N. J., Lunt M., Barrett E. M., Silman A. J., Symmons D. P. M., Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis and Rheumatism 2002 46 8 2010 2019 2-s2.0-0036675108 10.1002/art.10419
5. Goodson N. J., Symmons D. P. M., Scott D. G. I., Bunn D., Lunt M., Silman A. J., Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis and Rheumatism 2005 52 8 2293 2299 2-s2.0-23644453158 10.1002/art.21204 (Pubitemid 41117412)
6. Smolen J. S., Landewé R., Breedveld F. C., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases 2010 69 6 964 975 10.1136/ard.2009.126532
7. Furst D. E., Keystone E. C., So A. K., Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Annals of the Rheumatic Diseases 2013 72 supplement 2 ii2 ii34 10.1136/annrheumdis-2013-203348
8. Winiarska M., Bil J., Wilczek E., Wilczynski G. M., Lekka M., Engelberts P. J., Mackus W. J. M., Gorska E., Bojarski L., Stoklosa T., Nowis D., Kurzaj Z., Makowski M., Glodkowska E., Issat T., Mrowka P., Lasek W., Dabrowska-Iwanicka A., Basak G. W., Wasik M., Warzocha K., Sinski M., Gaciong Z., Jakobisiak M., Parren P. W. H. I., Golab J., Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Medicine 2008 5 3, article e64 0502 0517 2-s2.0-41549118473 10.1371/journal.pmed.0050064 (Pubitemid 351471699)
9. Deans J. P., Li H., Polyak M. J., CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002 107 2 176 182 2-s2.0-0036408912 10.1046/j.1365-2567.2002.01495.x (Pubitemid 35279043)
10. Janas E., Priest R., Wilde J. I., White J. H., Malhotra R., Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clinical and Experimental Immunology 2005 139 3 439 446 2-s2.0-14744284704 10.1111/j.1365-2249.2005.02720.x (Pubitemid 40333255)
11. Arts E. E. A., Jansen T. L., den Broeder A., Vonkeman H. E., Dutmer E., van de Laar M. A. F. J., van Riel P. L. C. M., Fransen J., Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Annals of the Rheumatic Diseases 2011 70 5 877 878 2-s2.0-79953325909 10.1136/ard.2010.136093
12. Das S., Matilla M. F., Dass S., Buch M. H., Rawstron A. C., Vital E. M., Emery P., Statins do not influence clinical response and B cell depletion after rituximab treatment in rheumatoid arthritis. Annals of the Rheumatic Diseases 2013 72 3 463 464 10.1136/annrheumdis-2012-202454
13. Crowson C. S., Gabriel S. E., Towards improving cardiovascular risk management in patients with rheumatoid arthritis: the need for accurate risk assessment. Annals of the Rheumatic Diseases 2011 70 5 719 721 2-s2.0-79953309050 10.1136/ard.2010.145482